Obulwadde bwa Semaglutid (GLP-1)10mg

▎ Enzimba ya GLP-1

▎ Okunoonyereza ku GLP-1

Ensibuko y’okunoonyereza ku GLP-1 eri etya?

GLP-1 ye peptide-1 eringa glucagon y’omuntu (GLP-1) analog, esengekeddwa nga GLP-1 receptor agonist. GLP-1 busimu bwa butonde obufulumizibwa obutoffaali bw’ekyenda oluvannyuma lw’okulya. Kikola kinene mu kutumbula okufulumya insulini n’okuziyiza okufulumya glucagon, bwe kityo ne kitereeza emiwendo gya glucose mu musaayi. Enkulaakulana ya GLP-1 yasibuka mu kunoonyereza okw’obwegendereza ku mirimu gy’omubiri gya GLP-1. Wabula GLP-1 erina ekitundu ky’obulamu ekitono ennyo mu mubiri, ekimala eddakiika nga 1 ku 2 zokka, ekiva ku kusobola okuvunda olw’enziyiza za dipeptidyl peptidase-4 (DPP-4) mu mubiri. Okuvvuunuka obuzibu buno, bannassaayansi baakyusa ensengekera ya GLP-1 nga bayita mu kukyusa amino asidi ebitongole n’okugattako ebibinja ebikuuma, ne bayongera ku buziyiza bwayo eri enziyiza za DPP-4 era bwe batyo ne bawangaaza ebbanga lyayo ery’okukola ^[1] . Mu nsengekera ya GLP-1, alanine mu kifo eky’omunaana ekyusiddwamu α-aminoisobutyric acid (Aib). Enkyukakyuka eno tekoma ku kulongoosa butebenkevu bwa ddagala wabula era enyweza okusiba kwalyo ku GLP-1 receptor (Ma H, 2020). Okugatta ku ekyo, olujegere lw’amasavu olw’enjawulo oluyungiddwa ku C-terminus yaalwo, oluyungiddwa nga luyita mu γ-glutamine ku bisigalira bya lysine, lwongera okwongera ku kitundu ky’obulamu, ne kisobozesa okukuba empiso omulundi gumu buli wiiki oba omulundi gumu buli lunaku mu kamwa ^[1] . Mu kusooka nga yeesigamiziddwa ku kunoonyereza n’okukyusakyusa mu butonde bwa GLP-1, GLP-1 egenderera okuwa obujjanjabi obusingako obulungi eri abalwadde abalina sukaali ow’ekika eky’okubiri ^{[1, 2]} . Oluvannyuma lw’okulongoosa enzimba, ekuuma emirimu gy’omubiri gya GLP-1 ate nga erongoosa nnyo eby’obugagga byayo eby’eddagala, n’efuuka agonist enkulu ekola ebbanga eddene erikwata GLP-1. Okunoonyereza n’okukola GLP-1 kwa makulu nnyo mu kujjanjaba obulwadde bwa sukaali obw’ekika eky’okubiri, nga kiwa abalwadde eby’okulonda ebipya. Nga elongoosa ensengekera, evvuunuka ekizibu ky’ekitundu ky’obulamu ekitono ekya GLP-1 ow’obutonde, okutumbula obutebenkevu bw’eddagala n’obudde bw’okukola.

Enkola ki ey’okukola kwa GLP-1?

GLP-1 ye glucagon-like peptide-1 (GLP-1) receptor agonist ekola ebbanga eddene, era enkola yaayo ey’okukola eri bweti:

Okulungamya Glucose mu musaayi: Ng’ekirungo ekipya ekiringa glucagon-like peptide-1 receptor agonist (GLP-1RA), GLP-1 okusinga ekendeeza ku kwegomba kw’abalwadde emmere n’okukendeeza ku kwegomba kwabwe emmere erimu amasavu amangi nga enyigiriza okwagala okulya. Kitereeza ekifo eky’okuliisa mu hypothalamus, okukendeeza ku mmere gye balya, okwongera okukkuta, okuziyiza okufulumya amazzi mu lubuto, n’okukendeeza ku kutambula kw’olubuto n’ekyenda, bwe kityo ne kituuka ku kiruubirirwa ky’okugejja. Okugejja kiyamba okulongoosa obuziyiza bwa insulini n’okwongera okutereeza emiwendo gya glucose mu musaayi ^[3] (Kim HS, 2021). GLP-1 ereeta okugejja mu biwuka okuyita mu makubo g’obusimu agasaasaanyiziddwa. Okunoonyereza kulaga nti GLP-1 ekola butereevu ku bitundu nga ekikolo ky’obwongo, septal nucleus, ne hypothalamus. Wadde nga tesomoka kiziyiza omusaayi n’obwongo, ekwatagana n’obwongo okuyita mu bitundu by’omubiri ebyetooloola n’ebitundu ebitongole okumpi n’ennywanto. Kireetera central c-Fos activation mu bitundu by’obwongo 10, omuli ebitundu by’obwongo obw’emabega ebigendereddwa butereevu GLP-1 n’ebitundu eby’okubiri ebitaliiko nkolagana ya GLP-1R butereevu, gamba nga lateral parabrachial nucleus. Okwekenenya okw’obwengula kulaga nti okukola kuyinza okuba nga kwekuusa ku kukomya emmere efugibwa obusimu obuyitibwa neurons mu lateral parabrachial nucleus, bwe kityo ne kitereeza emiwendo gya glucose mu musaayi ^[4]..

Okulungamya olubuto: GLP-1 ekola ku bikwata GLP-1 mu nkola y’olubuto. Okuyita mu kkubo erikwata ku busimu bwa vagus, kikola ku bitundu mu bwongo nga nucleus y’omukutu ogw’omuntu omu ne dorsal motor nucleus y’obusimu bwa vagus okulung’amya entambula y’olubuto n’ekyenda. Kiyinza okuziyiza okukonziba kw’omusuwa gw’omu lubuto, okwongera okusika omuguwa gw’omu lubuto, okwongera ku budde emmere gy’emala mu lubuto, n’okulwawo okuyingira mu lubuto, ne kiziyiza okulinnya amangu kwa glucose mu musaayi oluvannyuma lw’okulya n’okufuula enkyukakyuka za glucose mu musaayi okutebenkera ^[5] (Katsurada K, 2016). Okugatta ku ekyo, GLP-1 ekola ku bikwata GLP-1 mu nkola y’obusimu obw’omu makkati, okusinga mu bitundu nga arcuate nucleus ne paraventricular nucleus of the hypothalamus. Kiziyiza okufulumya ebintu ebisitula okwagala okulya nga neuropeptide Y (NPY) ne agouti-related protein (AgRP), ate mu kiseera kye kimu kikola obusimu obuyitibwa pro-opiomelanocortin (POMC) neurons, okutumbula okufulumya obusimu obusitula α-melanocyte (α-MSH) ^[5] . Ebikolwa bino bireeta okuwulira ng’okkuta, bikendeeza enjala, n’okukendeeza ku mmere gy’olya, mu ngeri etali ya butereevu ne bikola bulungi ku kufuga glucose mu musaayi.

Okukuuma emisuwa: GLP-1 esobola okutumbula obutoffaali bw’emisuwa okufulumya ensonga ezigaziya emisuwa nga nitric oxide (NO), okutumbula obusobozi bw’okugaziya emisuwa n’okulongoosa enkola y’okufuyira omusaayi. Mu kiseera kye kimu, kiziyiza okuddamu kw’okuzimba n’okunyigirizibwa okw’okwokya, kikendeeza ku kwonooneka kw’obutoffaali bw’emisuwa, era kikendeeza ku bulabe bw’okuzimba emisuwa. Ekirala, mu kukendeeza ku njagala n’okulya emmere, GLP-1 eyamba mu kugejja, etereeza obuzibu bwa ssukaali ow’amasavu, ekendeeza ku miwendo gya triglycerides ne low-density lipoprotein cholesterol (LDL-C), era eyongera ku muwendo gwa high-density lipoprotein cholesterol (HDL-C). Era kiyinza okuba n’emigaso ku puleesa nga kitereeza enkola y’omusaayi mu kibumba n’emirimu gy’obusimu, okukendeeza ku bulabe bwa puleesa n’ensonga ezireeta endwadde z’emisuwa ^[6]..

GLP-1 n’okulungamya okuwandiika kw’okukyusa WAT ​​okudda mu BAT n’okukola kwa BAT.

Ensibuko: PubMed ^{[12] .}

Biki ebikulu ebigezeseddwa n’okunoonyereza?

Design and Optimization of Chemical Structure: Bwe baali bakola dizayini ya GLP-1, enkola y’okusiba okuddamu ku albumin yakwatibwa okwongera ku bbanga eddagala lye limala nga likola. Nga tusalawo omugatte ogusinga obulungi ogwa asidi z’amasavu n’ebiyunga, ate nga tukuuma obulungi bw’ekirungo ekikwata GLP-1 (GLP-1R), obusobozi bw’okusiba albumin bwasukkiridde ^[7]..

Okukozesa eddagala: GLP-1 ye glucagon-like peptide-1 receptor agonist (GLP-1 RA) nga erina ekitundu ky’obulamu ekiwanvu ennyo eky’okuggyawo, ekisobozesa okukuba empiso omulundi gumu buli wiiki wansi w’olususu. Mu balwadde ba sukaali ow’ekika eky’okubiri (T2DM), ekikolwa ky’okugejja eky’okukuba empiso ya GLP-1 omulundi gumu buli wiiki wansi w’olususu kisinga ku GLP-1RA endala eziweebwa omulundi gumu buli wiiki. Mu kugezesebwa okwa phase II dose-exploration ku balwadde abagejjulukuka abatalina T2DM, empiso ya GLP-1 omulundi gumu buli lunaku wansi w’olususu yalaga nti ekendeeza ku buzito okusinga placebo ne liraglutide 3.0 mg omulundi gumu buli lunaku. Diguli y’okugejja okuva ku GLP-1 mu kunoonyereza kuno yasukka omutindo gw’eddagala erigejja ogwateekebwawo ekitongole ky’eddagala ekya Bulaaya (EMA) n’ekitongole kya Amerika ekivunaanyizibwa ku by’emmere n’eddagala (FDA), era tekirina bulabe, ekiraga nti empiso ya GLP-1 omulundi gumu buli lunaku wansi w’olususu erina obusobozi okufuuka eddagala erikendeeza ku mugejjo mu biseera eby’omu maaso ^[8]..

Obujjanjabi bw’endwadde z’emisuwa n’emisuwa nga tulongoosa enkola y’omutima: Ebyavudde mu kugezesebwa kwa STEP-HFpEF byalaga nti dose ennene antidiabetic glucagon-like peptide 1 agonist GLP-1 yalongoosa nnyo obubonero obukwatagana n’okulemererwa kw’omutima n’ekitundu ekikuumibwa ejection fraction (HFpEF) era n’ekendeeza ku mutindo gwa N-terminal pro-B-type natriuretic peptide (NT-proBNP) (NT-proBNP) nga bwe kiri. Okugezesebwa mu kunoonyereza kuzudde nti obujjanjabi obw’amangu ne GLP-1 busobola okwongera ku kusika omuguwa kw’emisuwa gy’omuntu emirundi egisukka mu esatu mu ngeri eyesigamiziddwa ku ddoozi, awatali kwongera ku mpisa ya arrhythmia. Ekikolwa kino kiyinza okuba nga kiva ku kweyongera mu kutwalibwa kwa Ca2+ okukolebwa sarcoplasmic reticulum. Obujjanjabi bwa dose ennene GLP-1 mu balwadde abalina omutima okulemererwa busobola okulongoosa enkola y’emisuwa, bwe kityo ne kiwummuza obubonero ^[9]..

GLP-1 enoonyezebwa okujjanjaba obulwadde bw’ekibumba obutali bwa mwenge (NASH): Enteekateeka entuufu eya GLP-1 ekoze kinene mu kulongoosa okufuga glucose mu musaayi, obuzito bw’omubiri, puleesa, amasavu mu musaayi, enkola y’obutoffaali bwa β, n’enkola y’emisuwa gy’omutima mu balwadde ba sukaali ow’ekika eky’okubiri. Okugatta ku ekyo, okukola eddagala eriweebwa mu kamwa erya GLP-1 kuyinza okuwa enkizo ey’enjawulo mu nsonga z’okugoberera obujjanjabi bw’abalwadde ^[7]..

Njawulo ki mu bikolwa by’okugejja ebya GLP-1 mu bantu ab’enjawulo?

Abantu abakulu abalina endwadde z’emisuwa n’emisuwa ezaaliwo edda, abagejjulukuka oba omugejjo naye nga tebalina ssukaali: Mu kugezesebwa kwa SELECT cardiovascular outcomes, GLP-1 yakendeeza ku bikulu ebizibu ebiva mu misuwa n’emisuwa ebitundu 20% mu bantu abakulu 17,604 abalina endwadde z’emisuwa n’emisuwa ezaaliwo edda, abagejjulukuka oba omugejjo, era nga tebalina sukaali ^[10] (Ryan DH, 2024). Mu kwekenneenya kuno okwalagirwa nga tekunnabaawo, abanoonyereza beekenneenya ebiva mu GLP-1 ku buzito bw’omubiri, ebiva mu anthropometric, obukuumi, n’okugumiikiriza okusinziira ku baseline body mass index (BMI). Abalwadde abafuna GLP-1 baafuna okukendeera okutambula obutasalako mu buzito bw’omubiri mu wiiki 65, okumala emyaka 4. Ku wiiki 208, bw’ogeraageranya n’ekibinja kya placebo, GLP-1 yaleetawo okukendeera kwa wakati mu buzito bw’omubiri (-10.2%), okwetooloola ekiwato (-7.7 cm), n’omugerageranyo gw’ekiwato n’obuwanvu (-6.9%), ate ekibinja kya placebo kyalina okukendeera kwa (-1.5%, -1.3 cm, ne -1.0%) okusinziira ku, era okugeraageranya kwonna ne placebo kwali kwa maanyi mu bibalo. Okugejja okw’amakulu mu bujjanjabi kwaliwo mu basajja n’abakazi, amawanga gonna, ebika by’omubiri, n’ebitundu. GLP-1 yali ekwatagana n’ebizibu eby’amaanyi ebitono. Ku buli kibinja kya BMI (<30, 30 okutuuka ku <35, 35 okutuuka ku <40, ne ≥40 kg/m²), ebiseera by’ebizibu eby’amaanyi ebya GLP-1 (omuwendo gw’ebintu ebyetegereza buli muntu-emyaka 100) byali wansi (43.23, 43.54, 51.07, ne 47.06 ku GLP-1, ne 50.48, 49.66, 52.73, ne 60.85 ku ddagala lya placebo). GLP-1 yali ekwatagana n’omutindo ogweyongera ogw’okuyimiriza ekintu ekigezeseddwa. Omutendera gwa BMI bwe gwakendeera, omuwendo gw’abayimirizaawo gweyongera. Mu kugezesebwa kwa SELECT, ku wiiki 208, GLP-1 yaleeta okugejja okw’amaanyi mu bujjanjabi n’okulongoosa mu miwendo gya anthropometric bw’ogeraageranya n’ekirungo kya placebo, era okugejja kwasigala okumala emyaka 4.

Abantu ssekinnoomu abagejjulukuka oba abagejjulukuka naye nga tebalina sukaali: Okwekenenya okutegekeddwa kwekenneenya obulungi n’obukuumi bwa GLP-1 mu bantu ssekinnoomu abagejjulukuka oba abagejjulukuka naye nga tebalina sukaali ^[11] . Okuddamu okwetegereza kuno kwagatta ebivudde mu kugezesebwa okw’obujjanjabi okungi, nga kussa essira ku bikolwa bya GLP-1 ku kugejja, ebipimo by’enkyukakyuka y’emmere, n’ebiva mu bulamu okutwalira awamu. Ebivuddemu biraga nti GLP-1 yali ekwatagana n’okugejja ennyo n’okulongoosa mu bipimo by’obulamu ebikwatagana n’omugejjo, era eyinza okuba enkola ey’omuwendo ey’obujjanjabi eri abalwadde abagejjulukuka.

Abalwadde abatali ba ssukaali (obujulizi okuva mu RCTs eziwera): Mu kugezesebwa 4 okwafugibwa mu ngeri ey’ekifuulannenge, abalwadde abaali n’obuzito bw’omubiri obw’olubereberye obwa kkiro 96 okutuuka ku 105 baafuna empiso ya 2.4 mg eza GLP-1 wansi w’olususu buli wiiki n’okuyingira mu bulamu (okubudaabudibwa, emmere, n’okukola emirimu gy’omubiri) olw’obujjanjabi bw’okugejja. Okugezesebwa okumu okwa randomized controlled trial ku balwadde abatali ba ssukaali (N = 1961) kwalaga nti oluvannyuma lwa wiiki 68, okugejja kwa wakati kwali 15% (kg 15), nga kino kyali kya njawulo nnyo mu bibalo ku 2% (kg 3) mu kibinja kya placebo. Ekitundu ky’abalwadde abagejja ≥5% kyali 86% bw’ogeraageranya ne 32% mu kibinja kya placebo, era omuwendo ogwetaagisa okujjanjaba (NNT) = 2; ekitundu ky’abalwadde abagejja ≥10% kyali 69% bw’ogeraageranya ne 12% mu kibinja kya placebo, ne NNT = 2. Okugejja kwatuuka ku ddaala ku wiiki nga 60. Ebiseera by’ebizibu ebiva mu lubuto (AEs) byali 74% bw’ogeraageranya ne 48% mu kibinja kya placebo, n’omuwendo ogwetaagisa okukola obulabe (NNH) = 3. Ekitundu ky’abalwadde abayimiriza obujjanjabi olw’ebizibu ebizibu kyali 7% bw’ogeraageranya ne 3% mu kibinja kya placebo, ne NNH = 25. Mu kugezesebwa okulala okwafugibwa mu ngeri ey’ekifuulannenge n’okuyingira mu bulamu obw’amaanyi (N = 611), okugejja mu kibinja kya GLP-1 kwali 16% (kkiro 17), nga kino kyali kya njawulo nnyo mu bibalo ku 6% (kkiro 6) mu kibinja kya placebo. Mu dose-exploration randomized controlled trial eri abalwadde ba ssukaali (N = 1210), abalwadde baweebwa buli wiiki 2.4 mg za GLP-1, buli wiiki 1.0 mg za GLP-1, oba placebo. Oluvannyuma lwa wiiki 68, okugejja okwa wakati kwali 10% (2.4 mg), 7% (1.0 mg), ne 3% (placebo). Ekitundu ky’abalwadde abagejja ≥5% kyali 69% (2.4 mg), 57% (1.0 mg) bw’ogeraageranya ne 29% mu kibinja kya placebo. Ku ddoozi za 2.4 mg ne 1.0 mg, NNT = 9. Ebizibu ebyavaamu byali bifaanagana mu ddoozi ez’enjawulo. Mu kugezesebwa okufugibwa okukuuma obuzito (N = 803), abeetabye mu kugezesebwa abatali balwadde ba ssukaali baafuna obujjanjabi buli wiiki ne 2.4 mg za GLP-1 okumala wiiki 20, n’oluvannyuma ne baawulwamu mu ngeri ey’ekifuulannenge mu kibinja ekigenda mu maaso n’obujjanjabi bwa GLP-1 oba ekibinja kya placebo. Oluvannyuma lwa wiiki 48, ekibinja ekyagenda mu maaso n’obujjanjabi bwa GLP-1 kyakendeeza ku buzito bw’omubiri gwabwe ebitundu 8%, ate ekibinja kya placebo kyakendeera ebitundu 7% ku buzito bw’omubiri gwabwe.

Mu kumaliriza, GLP-1 ddagala lya GLP-1 receptor agonist nga lirina omugaso gw’okukozesa mu nnimiro eziwera. Mu by’obujjanjabi bwa sukaali, efuga bulungi emiwendo gya glucose mu musaayi nga yesiba ku bikwata GLP-1, okutumbula okufulumya insulini, n’okuziyiza okufulumya glucagon, ne kiwa enkola enkulu ey’obujjanjabi eri abalwadde ba sukaali ow’ekika eky’okubiri. Mu nsonga y’obujjanjabi bw’omugejjo, GLP-1 ekendeeza nnyo amaanyi agayingira ng’eyita mu nkola nga okuziyiza okulya emmere mu makkati n’okulwawo okufulumya amazzi mu lubuto, okuyamba abalwadde abagejjulukuka okugejja n’okulongoosa embeera yaabwe ey’okukyusakyusa emmere. Okugatta ku ekyo, GLP-1 era eraga essuubi eriyinza okukozesebwa mu kuziyiza n’okujjanjaba endwadde z’emisuwa. Okulongoosa kwayo ensonga z’obulabe eri emisuwa n’emisuwa kiwa enkola empya ey’okukendeeza ku bikolwa by’emisuwa n’emitima.

Ebikwata ku Muwandiisi

Ebintu ebyogeddwako waggulu byonna binoonyerezeddwako, birongooseddwa era ne bikung’aanyizibwa kkampuni ya Cocer Peptides.

Omuwandiisi wa Scientific Journal

Hegner P munoonyereza mu yunivasite y’e Regensburg. Omulimu gwe gukwata ku Chemistry, Cardiovascular System, ne Cardiology. Mu Chemistry, anoonyereza ku nkola ezikwatagana n’obulamu bw’emisuwa n’emitima. Mu kunoonyereza ku nkola y’emisuwa gy’omutima, anoonyereza ku nkola y’omutima n’emisuwa, ng’anoonya amagezi agakwata ku bujjanjabi. Okunoonyereza kwe ku Cardiology kwesigamye ku kuziyiza endwadde z’omutima, okuzuula n’okuzijjanjaba.

Ebintu Hegner by’akola bikulu nnyo. Okutegeera kwe okw’eddagala kuleetedde okukola eddagala eppya ery’emisuwa. Omulimu gwe ku nkola y’omutima n’emisuwa guyongedde okutegeera endwadde z’emisuwa. Mu bujjanjabi, okunoonyereza kwe kulongoosezza enzirukanya y’endwadde z’omutima, ne kusitula omutindo gw’okulabirira abalwadde. Okutwaliza awamu, enkola ya Hegner ey’eby’emikono mingi egaggawaza eddagala ly’emisuwa n’emisuwa, n’ewa essuubi okukendeeza ku buzito bw’endwadde n’ebiva mu balwadde ebirungi. Hegner P awandiikiddwa mu kiwandiiko ekijuliziddwa mu kiwandiiko ekijuliziddwa ^[9]..

▎ Ebiwandiiko Ebikwatagana

[1] Memon A, Tehrim M, Kumari B. GLP-1: enkya empya eri abalwadde ba ssukaali[J]. Journal of ekibiina ekigatta abasawo mu Pakistan, 2023,73 (3): 721.DOI: 10.47391 / JPMA.7558.

[2] Ma H, Huang W, Wang X, n’abalala. Ensengeka y’okutegeera mu kukola kwa GLP-1R okukolebwa molekyu entono agonist[J]. Okunoonyereza ku butoffaali, 2020,30 (12): 1140-1142.DOI: 10.1038 / s41422-020-0384-8.

[3] Kim HS, Jung C H. GLP-1 ey’omu kamwa, Agonist esooka okuyingizibwa mu Glucagon-Like Peptide-1 Receptor: Kyandiba Essasi ery’Obulogo eri ssukaali ow’ekika eky’okubiri?[J]. Ekitabo ky’ensi yonna ekya Sayansi wa Molekyulu, 2021,22 (18).DOI:10.3390/ijms22189936.

[4] Gabery S, Salinas CG, Paulsen SJ, n’abalala. GLP-1 ekendeeza ku buzito bw’omubiri mu biwuka ng’eyita mu makubo g’obusimu agasaasaanyiziddwa[J]. Jci Okutegeera, 2020,5 (6).DOI: 10.1172 / jci.okutegeera.133429.

[5] Katsurada K, Yada T. Ebikolwa by’obusimu eby’ekyenda n’obwongo ebiva mu glucagon-like peptide-1 ne receptor agonist yaayo[J]. Journal of okunoonyereza ku ssukaali, 2016, 7: 64-69.DOI: 10.1111 / jdi.12464.

[6] Ryan D. H., Lingvay I, Colhoun HM, n’abalala. GLP-1 Ebikosa ku biva mu misuwa gy’omutima mu bantu abagejjulukuka oba abagejjulukuka (SELECT) rationale and design[J]. Ekitabo ky’omutima mu Amerika, 2020,229:61-69.DOI:10.1016/j.ahj.2020.07.008.

[7] Knudsen LB, Lau J. Okuzuula n’okukulaakulanya Liraglutide ne GLP-1[J]. Ensalo mu by’obutonde bw’ensi, 2019,10.DOI:10.3389/fendo.2019.00155.

[8] Christou G. A., Katsiki N., Blundell J., n’abalala. GLP-1 nga eddagala erisuubiza eriziyiza omugejjo[J]. Okuddamu okwetegereza omugejjo, 2019, 20 (6): 805-815.DOI: 10.1111 / obr.12839.

[9] Hegner P, Seitz S, Schopka S, n’abalala. GLP-1 erongoosa enkola y’okukonziba mu atrium y’omuntu eyawuddwamu[J]. Ekitabo ky’omutima ekya Bulaaya, 2024,45.DOI:10.1093/eurheartj/ehae666.3729.

[10] Ryan D. H., Lingvay I, Deanfield J., n’abalala. Ebikolwa by’okugejja okumala ebbanga eddene ebya GLP-1 mu mugejjo awatali ssukaali mu kugezesebwa kwa SELECT[J]. Eddagala ly’obutonde, 2024, 30 (7): 2049-2057.DOI: 10.1038 / s41591-024-02996-7.

[11] Alanazi M, Alshahrani J. A., Aljaberi A. S., n’abalala. Ebikolwa bya GLP-1 mu bantu abalina omugejjo oba abagejjulukuka abatalina sukaali[J]. Cureus Journal of Sayansi w'Ebyobujjanjabi, 2024,16 (8).DOI: 10.7759 / cureus.67889.

[12] Papakonstantinou I, Tsioufis K, Katsi V. Okussa essira ku nkola y’okukola kwa GLP-1[J]. Ensonga eziriwo mu kiseera kino mu molekyu biology, 2024,46 (12): 14514-14541.DOI: 10.3390 / cimb46120872.

EBINTU BYONNNA N’AMAWULIRE GW’EBINTU EBIweereddwa KU MUTINDO GUNO BIKOZESEBWA KU KUSASANYA AMAWULIRE N’EBIKOLWA BY’OKUSOMESA BYOKA.  

Ebintu ebiweereddwa ku mukutu guno bigendereddwamu kunoonyereza mu kisenge (in vitro research) byokka. Okunoonyereza mu kisenge (in vitro research) (Olulattini: *mu ndabirwamu*, ekitegeeza mu bikozesebwa mu ndabirwamu) kukolebwa ebweru w’omubiri gw’omuntu. Ebintu bino si bya ddagala, tebikkiriziddwa kitongole kya Amerika ekivunaanyizibwa ku by’emmere n’eddagala (FDA), era tebirina kukozesebwa kuziyiza, kujjanjaba oba kuwonya mbeera yonna ya bujjanjabi, bulwadde oba bulwadde. Kikugirwa nnyo mu mateeka okuyingiza ebintu bino mu mubiri gw’omuntu oba ebisolo mu ngeri yonna.